NCT05490667 is a NA clinical trial of Anlotinib in Desmoid, sponsored by Henan Cancer Hospital.

Who is sponsoring NCT05490667?

NCT05490667 is sponsored by Henan Cancer Hospital.

What drugs are being tested in NCT05490667?

Interventions in NCT05490667: Anlotinib.

Is NCT05490667 still recruiting?

NCT05490667 is currently status unknown. Last updated 30 October 2023.

Last reviewed 2023-10-30 · How we verify

NCT05490667

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor

Status unknown NA Last updated 30 October 2023

What this trial tests

NA trial testing Anlotinib in Desmoid in 30 participants. Status unknown.

Timeline

20 August 2022

Primary endpoint
31 July 2024

31 July 2024

Quick facts

Lead sponsor	Henan Cancer Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	20 August 2022
Primary completion	31 July 2024
Estimated completion	31 July 2024
Sites	1 location across China

Drugs / interventions tested

Anlotinib — full drug profile →

Conditions studied

Desmoid — all drugs for Desmoid →

Sponsor

Henan Cancer Hospital

Who can join

Adults 10 to 72, any sex, with Desmoid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Thirty patients with desmoid tumors (invasive fibromatosis) will be recruited in the Department of Bone and Soft Tissue, Henan Cancer Hospital. This is a prospective, multicenter, single-arm clinical study to evaluate the efficacy and safety of anlotinib combined with chemotherapy in the treatment of inoperable advanced desmoid tumors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Desmoid Tumors: A Comprehensive Review.
Bektas M, Bell T, Khan S, Tumminello B, et al · · 2023 · cited 50× · PMID 37436594 · DOI 10.1007/s12325-023-02592-0
Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors.
Xu H, Hu J, Zhang Y, Zhuang A, et al · · 2026 · cited 1× · PMID 41504634 · DOI 10.1158/1078-0432.ccr-25-3128

Verify or expand the search:

Other trials of Anlotinib

Trials testing the same drug.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
NCT07376499 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 2 · not yet recruiting

Other recruiting trials for Desmoid

Currently open trials in the same condition.

NCT06502483 — PRISM for Depression and Anxiety in Young Adults With Cancer · NA · active not recruiting
NCT06268457 — Arterial Chemoembolization for the Treatment of Desmoid Fibromatosis · recruiting
NCT06224283 — Radiomics Compared With Conventional Response Criteria for Predicting Progression of Desmoid Tumor After Cryoablation · recruiting
NCT05919264 — FOG-001 in Locally Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · recruiting
NCT05091255 — Cryotherapy in the Treatment of Desmoid Tumors · NA · recruiting

Other Henan Cancer Hospital trials

Trials by the same sponsor.

NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05490667 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
Last refreshed: 30 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05490667.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing